EP1230351A1 - Variants alpha-amylase du type fungamyle - Google Patents

Variants alpha-amylase du type fungamyle

Info

Publication number
EP1230351A1
EP1230351A1 EP00974351A EP00974351A EP1230351A1 EP 1230351 A1 EP1230351 A1 EP 1230351A1 EP 00974351 A EP00974351 A EP 00974351A EP 00974351 A EP00974351 A EP 00974351A EP 1230351 A1 EP1230351 A1 EP 1230351A1
Authority
EP
European Patent Office
Prior art keywords
alpha
amylase
variant
fungamyl
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP00974351A
Other languages
German (de)
English (en)
Inventor
Henrik Bisgard-Frantzen
Allan Svendsen
Sven Pedersen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novozymes AS
Original Assignee
Novozymes AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novozymes AS filed Critical Novozymes AS
Priority to EP08152275A priority Critical patent/EP1980614A3/fr
Publication of EP1230351A1 publication Critical patent/EP1230351A1/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01001—Alpha-amylase (3.2.1.1)
    • A—HUMAN NECESSITIES
    • A21—BAKING; EDIBLE DOUGHS
    • A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
    • A21D8/00—Methods for preparing or baking dough
    • A21D8/02—Methods for preparing dough; Treating dough prior to baking
    • A21D8/04—Methods for preparing dough; Treating dough prior to baking treating dough with microorganisms or enzymes
    • A21D8/042—Methods for preparing dough; Treating dough prior to baking treating dough with microorganisms or enzymes with enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12C—BEER; PREPARATION OF BEER BY FERMENTATION; PREPARATION OF MALT FOR MAKING BEER; PREPARATION OF HOPS FOR MAKING BEER
    • C12C11/00—Fermentation processes for beer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12C—BEER; PREPARATION OF BEER BY FERMENTATION; PREPARATION OF MALT FOR MAKING BEER; PREPARATION OF HOPS FOR MAKING BEER
    • C12C5/00—Other raw materials for the preparation of beer
    • C12C5/004—Enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
    • C12N9/2411—Amylases
    • C12N9/2414—Alpha-amylase (3.2.1.1.)
    • C12N9/2417—Alpha-amylase (3.2.1.1.) from microbiological source
    • C12N9/242—Fungal source
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/14—Preparation of compounds containing saccharide radicals produced by the action of a carbohydrase (EC 3.2.x), e.g. by alpha-amylase, e.g. by cellulase, hemicellulase
    • C—CHEMISTRY; METALLURGY
    • C13—SUGAR INDUSTRY
    • C13K—SACCHARIDES OBTAINED FROM NATURAL SOURCES OR BY HYDROLYSIS OF NATURALLY OCCURRING DISACCHARIDES, OLIGOSACCHARIDES OR POLYSACCHARIDES
    • C13K1/00—Glucose; Glucose-containing syrups
    • C13K1/06—Glucose; Glucose-containing syrups obtained by saccharification of starch or raw materials containing starch
    • C—CHEMISTRY; METALLURGY
    • C13—SUGAR INDUSTRY
    • C13K—SACCHARIDES OBTAINED FROM NATURAL SOURCES OR BY HYDROLYSIS OF NATURALLY OCCURRING DISACCHARIDES, OLIGOSACCHARIDES OR POLYSACCHARIDES
    • C13K7/00—Maltose
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E50/00—Technologies for the production of fuel of non-fossil origin
    • Y02E50/10—Biofuels, e.g. bio-diesel

Definitions

  • TITLE Fungamyl-like Alpha-Amylase Variants
  • the present invention relates to alpha-amylase variants (mutants) of FungamylTM-l ⁇ ke alpha-amylases, m particular with improved thermal stability at acidic pH .
  • the invention also relates to the use of such variants.
  • Alpha-Amylases (alpha- 1 , 4-glucan-4-glucanohydrolases , EC. 3.2.1.1) constitute a group of enzymes which catalyze hydrolysis of starch and other linear and branched 1 , 4-glucos ⁇ d ⁇ c oligo- and polysaccharides .
  • Termamyl ® - like alpha-amylases A number of alpha-amylase referred to as "Termamyl ® - like alpha-amylases" and variants thereof are known from, e . g. , WO 90/11352, WO 95/10603, WO 95/26397, WO 96/23873 and WO 96/23874.
  • Termamyl-like alpha-amylases are very thermostable and therefore suitable for processes carried out at high temperatures such as starch liquefaction m dextrose production processes .
  • FungamylTM-l ⁇ ke alpha-amylases are alpha-amylases related to the alpha-amylase derived from Aspergillus oryzae (and shown m SEQ ID NO: 1) .
  • These Fungamyl-like alpha-amylases have a relatively low thermostability (the commercial product sold under the tradename FUNGAMYLTM by Novo Nordisk, Denmark, has a optimum around 55°C) and is therefore not suitable for processes carried out at high temperatures.
  • Fungamyl-like alpha- amylases are today used for making syrups for, e.g., the brewing industry. Such processes are operated at around 60°C resulting m that usually m the range of double the enzyme dosage must be used to compensate for the low thermostability. Further, at 55 °C infection problems may occur.
  • the object of the present invention is to provide Fungamyl- like alpha-amylase variant, m particular with improved thermostablility especially at acidic pH.
  • an alpha-amylase variant with improved thermostability'' means m the context of the present invention an alpha-amylase variant, which has a higher thermostability than corresponding parent alpha-amylases. The determination of thermostability is described below m the Materials and Method section.
  • the inventors have provided improved Fungamyl-like alpha- amylase variants as will be described further below.
  • a goal of the work underlying the present invention was to improve the thermal stability, in particular at acidic pH of Fungamyl-like alpha-amylases.
  • thermostability Identifying positions and/or regions to be mutated to obtain improved thermostability
  • MD simulations indicate the mobility of the ammo acids the protein structure (see McCammon, JA and Harvey, SC . , (1987), "Dynamics of proteins and nucleic acids”. Cambridge University Press . ) .
  • Such protein dynamics are of en compared to the crystallographic B- factors (see Stout, GH and Jensen, LH, (1989), , ⁇ X-ray structure determination", Wiley) or the B-factors themselves.
  • the pH related mobility of residues are simulated. Regions having the highest mobility or flexibility (here isotropic fluctuations) are selected for random mutagenesis.
  • the present invention relates to a variant of a parent Fungamyl-like alpha-amylase comprising one or more mutations in the regions and positions described further below.
  • Ala30Asn or A3ON a deletion of alanine in the same position is shown as: Ala30* or A30* and insertion of an additional amino acid residue, such as lysine, is shown as:
  • a deletion of a consecutive stretch of amino acid residues, such as amino acid residues 30-33, is indicated as (30-33)* or ⁇ (A30-N33) .
  • Ala30Asp + Glu34Ser or A30N+E34S representing mutations in positions 30 and 34 substituting alanine and glutamic acid for asparagine and serine, respectively.
  • Multiple mutations may also be separated as follows, i.e., meaning the same as the plus sign: Ala30Asp/Glu34Ser or A30N/E34S
  • (A) in position 30 is mentioned, but not specified, or specified as ⁇ , A30X", it is to be understood that the alanine may be deleted or substituted for any other amino acid, i.e., any one of: R,N,D,A,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V.
  • Fungamyl-like alpha-amylases Parent Fungamyl-like alpha-amylase are according to the present invention enzymes with alpha-amylase activity which either have at least 60%, preferably at least 70%, more preferably at least 80%, even more preferably at least 90%, even more preferably at least 93%, even more preferably at least 95%, even more preferably at least 97%, even more preferably at least 99% identity to the DNA sequence shown in SEQ ID NO: 1 encoding the alpha-amylase and/or the mature part of the alpha-amylase protein sequence shown in SEQ ID NO: 2 and/or structurally resembles the three-dimensional structure of the FUNGAMYL ® alpha-amylase shown in SEQ ID NOS: 1 and 2, and further disclosed in the Protein Data Base (PDB) (www.rcsb.org) file 6TAA
  • PDB Protein Data Base
  • alpha-amylases covered by the definition "Fungamyl-like alpha-amylases” include the Aspergillus oryzae TAKA alpha-amylase (EP 238 023) and shown in SEQ ID NO: 2, and the A . niger alpha-amylase disclosed in EP 383,779 B2 (section [0037] (see also the cloning of the A . niger gene in Example 1) .
  • the Fungamyl-like alpha-amylase is derived from a fungal organism, in particular of the genus Aspergillus , in particular A . oryzae or A . niger.
  • Fungamyl ® is a fungal alpha-amylase obtained from a selected strain of
  • Aspergillus oryzae In the starch industry, Fungamyl ® is used for production of high maltose syrups, 45-60% maltose (2-7% glucose) or high conversion syrups, DE 60-70, 35-43% glucose, 30-37% maltose.
  • Other commercial fungal alpha-amylases include ClaraseTM (from Genencor Int., USA) derived from Aspergillus oryzae; and MaltamylTM (from Enzyme Biosystems) derived from Aspergillus niger.
  • FUNGAMYL ® (and similar products) is added during fermentation in order to increase fermentability of the wort .
  • FUNGAMYL ® may be used for liquefaction of starch in a distillery mash if the existing equipment favors low-temperature liquefaction (55-60°C) .
  • FUNGAMYL ® (and similar products) is also used for baking and can be used for all types of bread and baked products. For instance FUNGAMYL ® improves the dough stability, result in greater bread volume, improves crumb softness and give the crust a darker color.
  • the invention relates to a variant of a parent Fungamyl-like alpha-amylase comprising one or more mutation (s) in the following positions (s) or region (s) in the amino acid sequence shown in NO: 2:
  • Region 468-475 and/or in a corresponding position or region in a homologous Fungamyl-like alpha-amylase which displays at least 60% identity with the amino acid sequences shown in SEQ ID NO:
  • the region mutated is Region 98-110.
  • the region mutated is Region 98-110, more specifically one or more of the following positions: 98,99,100,101,102,103, 104,105,106,107,108,109,110.
  • 106V,L,N,D,Q,E preferably V
  • the region mutated is Region 150-160, more specifically one or more of the following positions: 150,151,152, 153,154, 155, 156,157,158, 159,160.
  • region mutated is Region 161-167, more specifically one or more of the following positions: 161, 162,
  • the region mutated is Region 280-288, more specifically one or more of the following positions: 280,281,282,283,284,285,286,287,288.
  • 281X preferably T,A
  • 282X preferably S,T
  • Region 448-455 is Region 448-455 more specifically one or more of the following positions:
  • 448X preferably A, L,Y, S,T; 449x, preferably L,V,S,T;
  • region mutated is Region 468-475 more specifically one or more of the following positions:
  • One object of the invention is to make the Fungamyl-like alpha-amylase more acidic in comparison to the parent alpha- amylase (i.e., corresponding un-mutated alpha-amylase).
  • That a Fungamyl-like alpha-amylase variant is more acidic than the parent Fungamyl-like alpha-amylase means that the stability at acidic pH is higher that for the corresponding parent alpha-amylase. That the amylase is more acidic may be determined as described m the "Materials & Methods'' section.
  • the term "acidic pH” means at least the context of the present invention a pH m the range from 4-6, such as 4-5, particular 4.2-4.7.
  • One object of the invention is to provide a more thermostable Fungamyl-like alpha-amylase.
  • That a Fungamyl-like alpha-amylase variant is more thermostable than the parent Fungamyl-like alpha-amylase means that the temperature optimum has been pushed towards a higher temperature. That the amylase is more thermostable may be determined as described the "Materials & Methods" section.
  • thermostable fungal alpha-amylases Providing more thermostable fungal alpha-amylases is desired because it renders a more efficient and/or faster liquefaction step possible. Further, the liquefaction temperature is less sensitive and may even be increased (i.e., less cooling necessary. Further, the risk of infection is also reduced.
  • variants of the invention may have both a more stable at acidic pH and be more thermostable, in particular at acidic pH.
  • the homology (identity) referred to above of the parent alpha-amylase is determined as the degree of identity between two protein or DNA sequences indicating a derivation of the first sequence from the second.
  • the homology (identity) may suitably be determined by means of computer programs known m the art such as GAP provided the GCG program package (Program Manual for the Wisconsin Package, Version 8, August 1994, Genetics Computer Group, 575 Science Drive, Madison, Wisconsin, USA 53711) (Needleman, S.B. and Wunsch, CD., (1970), Journal of Molecular Biology, 48, p. 443-453).
  • the (default) GAP creation penalty is 5.0 and the GAP extension penalty of 0.3, respectively, for nucleic acidic sequence comparison; and (default) GAP creation penalty is 3.0 and GAP extension penalty of 0.1, respectively, for protein sequence comparison.
  • GAP uses the method of Needleman and Wunsch, (1970) , J.Mol. Biol . 48, p.443-453, to make alignments and to calculate the identity.
  • a parent Fungamyl-like alpha-amylase has a degree of identity preferably of at least 60%, such as 70%, at least 80%, at least 90%, more preferably at least 95%, more preferably at least 97%, and most preferably at least 99% with the mature part of the ammo acid sequence shown m SEQ ID NO:
  • the variant of the invention has improved thermal stability, particular at acidic pH.
  • Oligonucleotide probes used m the characterisation of the Fungamyl-like alpha-amylase may suitably be prepared on the basis of the full or partial nucleotide or ammo acid sequence of the alpha-amylase m question.
  • Suitable conditions for testing hybridisation involve pre- soak g m 5xSSC and prehyb ⁇ dizmg for 1 hour at -40 °C m a solution of 20% formamide, 5xDenhardt ' s solution, 50mM sodium phosphate, pH 6.8, and 50mg of denatured sonicated calf thymus DNA, followed by hybridisation the same solution supplemented with 100 mM ATP for 18 hours at 40°C, followed by three times washing of the filter m 2xSSC, 0.2% SDS at 40°C for 30 minutes (low stringency) , preferred at 50°C (medium stringency) , more preferably at 65°C (high stringency) , even more preferably at 75°C (very high stringency) . More details about the hybridisation method can be found Sambrook et al . ,
  • derived from is intended not only to indicate an alpha-amylase produced or producible by a strain of the organism m question, but also an alpha-amylase encoded by a DNA sequence isolated from such strain and produced m a host organism transformed with said DNA sequence.
  • the term is intended to indicate an alpha-amylase, which is encoded by a DNA sequence of synthetic and/or cDNA origin and which has the identifying characteristics of the alpha-amylase m question.
  • the parent alpha-amylase may be a variant of a naturally occurring alpha- amylase, i.e., a variant, which is the result of a modification (insertion, substitution, deletion) of one or more ammo acid residues of the naturally occurring alpha-amylase.
  • DNA sequence encoding an Fungamyl-like alpha- amylaseCloning a DNA sequence encoding an a-amylaseCloning a DNA sequence encoding an a-amylase
  • the DNA sequence encoding a parent Fungamyl-like alpha-amylase may be isolated from any cell or microorganism producing alpha-amylases, using various methods well known m the art.
  • a genomic DNA and/or cDNA library should be constructed using chromosomal DNA or messenger RNA from the organism that produces the alpha-amylase to be studied.
  • labeled oligonucleotide probes may be synthesized and used to identify alpha-amylase-encoding clones from a genomic library prepared from the organism m question.
  • a labelled oligonucleotide probe containing sequences homologous to another known alpha-amylase gene could be used as a probe to identify alpha-amylase-encodmg clones, using hybridization and washing conditions of lower stringency.
  • Yet another method for identifying alpha-amylase-encodmg clones would involve inserting fragments of genomic DNA into an expression vector, such as a plasmid, transforming alpha- amylase-negative bacteria with the resulting genomic DNA library, and then plating the transformed bacteria onto agar containing a substrate for alpha-amylase ( i . e . , maltose), thereby allowing clones expressing the alpha-amylase to be identified.
  • the DNA sequence encoding the enzyme may be prepared synthetically by established standard methods, e . g. the phosphoroamidite method described S.L. Beaucage and M.H. Caruthers, (1981), Tetrahedron Letters 22, p.
  • oligonucleotides are synthesized, e . g. , m an automatic DNA synthesizer, purified, annealed, ligated and cloned in appropriate vectors.
  • the DNA sequence may be of mixed genomic and synthetic origin, mixed synthetic and cDNA origin or mixed genomic and cDNA origin, prepared by ligatmg fragments of synthetic, genomic or cDNA origin (as appropriate, the fragments corresponding to various parts of the entire DNA sequence) , m accordance with standard techniques.
  • the DNA sequence may also be prepared by polymerase chain reaction (PCR) using specific primers, for instance as described US 4,683,202 or R.K. Saiki et al., (1988), Science 239, pp. 487-491.
  • mutations may be introduced using synthetic oligonucleotides. These oligonucleotides contain nucleotide sequences flanking the desired mutation sites.
  • a smgle-stranded gap of DNA, the alpha-amylase-encodmg sequence is created m a vector carrying the alpha-amylase gene.
  • the synthetic nucleotide, bearing the desired mutation is annealed to a homologous portion of the smgle-stranded DNA.
  • telomere sequence may be synthesized by using a chemically synthesized DNA strand as one of the primers in the PCR reactions. From the PCR-generated fragment, a DNA fragment carrying the mutation may be isolated by cleavage with restriction endonucleases and reinserted into an expression plasmid.
  • Random mutagenesis is suitably performed either as localized or region-specific random mutagenesis in at least three parts of the gene translating to the amino acid sequence shown in question, or within the whole gene.
  • the random mutagenesis of a DNA sequence encoding a parent glucoamylase may be conveniently performed by use of any method known in the art .
  • a further aspect of the present invention relates to a method for generating a variant of a parent Fungamyl-like alpha-amylase, wherein the variant exhibits increased thermal stability, especially at acidic pH, relative to the parent, the method comprising:
  • Step (a) of the above method of the invention is preferably performed using doped primers, as described m the working examples herein (vide infra) .
  • the random mutagenesis may be performed by use of a suitable physical or chemical mutagenizmg agent, by use of a suitable oligonucleotide, or by subjecting the DNA sequence to PCR generated mutagenesis.
  • the random mutagenesis may be performed by use of any combination of these mutagenizmg agents.
  • the mutagenizmg agent may, e . g . , be one, which induces transitions, transversions , inversions, scrambling, deletions, and/or insertions.
  • Examples of a physical or chemical mutagenizmg agent suitable for the present purpose include ultraviolet (UV) irradiation, hydroxylamme, N-methyl-N ' -nitro-N-nitrosoguamdme (MNNG) , O-methyl hydroxylamme, nitrous acid, ethyl methane sulphonate (EMS), sodium bisulphite, formic acid, and nucleotide analogues.
  • UV ultraviolet
  • MNNG N-methyl-N ' -nitro-N-nitrosoguamdme
  • EMS ethyl methane sulphonate
  • sodium bisulphite formic acid
  • nucleotide analogues examples include ultraviolet (UV) irradiation, hydroxylamme, N-methyl-N ' -nitro-N-nitrosoguamdme (MNNG) , O-methyl hydroxylamme, nitrous acid, ethyl methane sulphonate (
  • the oligonucleotide may be doped or spiked with the three non-parent nucleotides durmg the synthesis of the oligonucleotide at the positions, which are to be changed.
  • the doping or spiking may be done so that codons for unwanted ammo acids are avoided.
  • the doped or spiked oligonucleotide can be incorporated into the DNA encoding the glucoamylase enzyme by any published technique, using, e . g . , PCR, LCR or any DNA polymerase and ligase as deemed appropriate.
  • the doping is carried out using "constant random doping" , in which the percentage of wild type and mutation in each position is predefined.
  • the doping may be directed toward a preference for the introduction of certain nucleotides, and thereby a preference for the introduction of one or more specific amino acid residues.
  • the doping may be made, e . g. , so as to allow for the introduction of 90% wild type and 10% mutations in each position.
  • An additional consideration in the choice of a doping scheme is based on genetic as well as protein- structural constraints.
  • the doping scheme may be made by using the DOPE program which, inter alia , ensures that introduction of stop codons is avoided.
  • PCR-generated mutagenesis When PCR-generated mutagenesis is used, either a chemically treated or non-treated gene encoding a parent glucoamylase is subjected to PCR under conditions that increase the mis- incorporation of nucleotides (Deshler 1992; Leung et al . , Technique, Vol .1 , 1989, pp. 11-15).
  • a mutator strain of E. coli (Fowler et al . , Molec . Gen. Genet., 133, 1974, pp. 179-191), S . cereviseae or any other microbial organism may be used for the random mutagenesis of the DNA encoding the glucoamylase by, e . g . , transforming a plasmid containing the parent glycosylase into the mutator strain, growing the mutator strain with the plasmid and isolating the mutated plasmid from the mutator strain. The mu-ta-ted plasmid may be subsequently transformed into the expression organism.
  • the DNA sequence to be mutagenized may be conveniently present in a genomic or cDNA library prepared from an organism expressing the parent glucoamylase.
  • the DNA sequence may be present on a suitable vector such as a plasmid or a bacteriophage, which as such may be incubated with or otherwise exposed to the mutagenising agent.
  • the DNA to be mutagenized may also be present in a host cell either by being integrated in the genome of said cell or by being present on a vector harboured in the cell.
  • the DNA to be mutagenized may be in isolated form. It will be understood that the DNA sequence to be subjected to random mutagenesis is preferably a cDNA or a genomic DNA sequence.
  • telomere amplification may be performed m accordance with methods known m the art, the presently preferred method being PCR-generated amplification using oligonucleotide primers prepared on the basis of the DNA or ammo acid sequence of the parent enzyme.
  • the mutated DNA is expressed by cultu ⁇ ng a suitable host cell carrying the DNA sequence under conditions allowing expression to take place.
  • the host cell used for this purpose may be one which has been transformed with the mutated DNA sequence, optionally present on a vector, or one which was carried the DNA sequence encoding the parent enzyme during the mutagenesis treatment.
  • suitable host cells are the following: gram positive bacteria such as Bacillus subtilis , Bacillus licheniformis , Bacillus lentus, Bacillus brevis , Bacillus stearothermophilus , Bacillus alkalophilus, Bacillus amyloliquefaci ens , Bacillus coagulans , Bacillus circulans, Bacillus lautus, Bacillus megaterium, Bacillus thuringiensis, Strepto yces li vidans or Streptomyces murinus; and gram-negative bacteria such as E. coli .
  • gram positive bacteria such as Bacillus subtilis , Bacillus licheniformis , Bacillus lentus, Bacillus brevis , Bacillus stearothermophilus , Bacillus alkalophilus, Bacillus amyloliquefaci ens , Bacillus coagulans , Bacillus circulans, Bacillus lautus, Bacillus megaterium,
  • the mutated DNA sequence may further comprise a DNA sequence encoding functions permitting expression of the mutated DNA sequence .
  • the random mutagenesis may be advantageously localized to a part of the parent alpha-amylase m question. This may, e . g. , be advantageous when certain regions of the enzyme have been identified to be of particular importance for a given property of the enzyme, and when modified are expected to result a variant havmg improved properties. Such regions may normally be identified when the tertiary structure of the parent enzyme has been elucidated and related to the function of the enzyme.
  • the localized, or region-specific, random mutagenesis is conveniently performed by use of PCR generated mutagenesis techniques as described above or any other suitable technique known m the art.
  • the DNA sequence encoding the part of the DNA sequence to be modified may be isolated, e . g. , by insertion into a suitable vector, and said part may be subsequently subjected to mutagenesis by use of any of the mutagenesis methods discussed above.
  • Alternative methods for providing variants of the invention include gene shuffling, e . g. , as described m WO 95/22625 (from Affymax Technologies N.V.) or m WO 96/00343 (from Novo Nordisk A/S) , or other corresponding techniques resulting in a hybrid enzyme comprising the mutat ⁇ on(s), e.g., substitution (s) and/or deletion, question.
  • a DNA sequence encoding the variant produced by methods described above, or by any alternative methods known m the art can be expressed, enzyme form, using an expression vector which typically includes control sequences encoding a promoter, operator, ⁇ bosome binding site, translation initiation signal, and, optionally, a repressor gene or various activator genes.
  • the recombmant expression vector carrying the DNA sequence encoding an alpha-amylase variant of the invention may be any vector which may conveniently be subjected to recombmant DNA procedures, and the choice of vector will often depend on the host cell into which it is to be introduced.
  • the vector may be one which, when introduced into a host cell, is integrated into the host cell genome and replicated together with the chromosome (s) into which it has been integrated. Examples of suitable expression vectors include pMT838.
  • the DNA sequence should be operably connected to a suitable promoter sequence .
  • the promoter may be any DNA sequence, which shows transcriptional activity m the host cell of choice and may be derived from genes encoding proteins either homologous or heterologous to the host cell.
  • suitable promoters for directing the transcription of the DNA sequence encoding an alpha-amylase variant of the invention, especially m a bacterial host are the promoter of the lac operon of E.
  • coli the Streptomyces coelicolor agarase gene dagA promoters, the promoters of the Bacillus licheniformis alpha-amylase gene ( a yL) , the promoters of the Bacillus stearothermophilus maltogenic amylase gene ( a yM) , the promoters of the Bacillus amyloliquefaciens alpha-amylase ( amyQ) , the promoters of the Bacillus subtilis xylA and xylB genes etc.
  • useful promoters are those derived from the gene encoding A .
  • TPI riose phosphate isomerase
  • S . cerevisiae Alber et al . (1982), J. Mol . Appl . Genet 1, p. 419-434
  • Rhizo- mucor iehei aspartic protemase A . niger neutral alpha- amylase, A . niger acid stable alpha-amylase, A . niger glu- coamylase, Rhizomucor miehei lipase, A . oryzae alkaline protease, A . oryzae triose phosphate isomerase or A . nidulans acetamidase .
  • the expression vector of the mvention may also comprise a suitable transcription terminator and, m eukaryotes, poly- adenylation sequences operably connected to the DNA sequence encoding the alpha-amylase variant of the invention. Termination and polyadenylation sequences may suitably be derived from the same sources as the promoter.
  • the vector may further comprise a DNA sequence enabling the vector to replicate m the host cell m question.
  • sequences are the origins of replication of plasmids pUC19, pACYC177, pUBHO, pE194, pAMBl and pIJ702.
  • the vector may also comprise a selectable marker, e.g. a gene the product of which complements a defect the host cell, such as the dal genes from B . subtilis or B . licheniformis , or one which confers antibiotic resistance such as ampicillm, kanamycm, chloramphenicol or tetracyclm resistance.
  • the vector may comprise Aspergillus selection markers such as amdS, argB, niaD and sC, a marker giving rise to hygromycm resistance, or the selection may be accomplished by co-transformation, e . g. , as described m WO 91/17243.
  • Aspergillus selection markers such as amdS, argB, niaD and sC, a marker giving rise to hygromycm resistance, or the selection may be accomplished by co-transformation, e . g. , as described m WO 91/17243.
  • the cell of the invention is advantageously used as a host cell m the recombmant production of an alpha-amylase variant of the invention.
  • the cell may be transformed with the DNA construct of the invention encoding the variant, conveniently by integrating the DNA construct (m one or more copies) m the host chromosome. This integration is generally considered to be an advantage as the DNA sequence is more likely to be stably maintained m the cell . Integration of the DNA constructs into the host chromosome may be performed according to conventional methods, e . g. , by homologous or heterologous recombination.
  • the cell may be transformed with an expression vector as described above m connection with the different types of host cells.
  • the cell of the invention may be a cell of a higher organism such as a mammal or an insect, but is preferably a microbial cell, e.g., a bacterial or a fungal (including yeast) cell.
  • suitable bacteria are Gram-positive bacteria such as Bacillus subtili s , Bacillus licheniformis, Bacillus lentus, Bacillus brevis, Bacillus stearothermophilus, Bacillus alkalophilus , Bacillus amyloliquefaci ens, Bacillus coagulans, Bacillus circulans, Bacillus lautus , Bacillus megaterium, Ba - cillus thuringiensis, or Streptomyces lividans or Streptomyces murinus, or gram-negative bacteria such as E. coli .
  • the transformation of the bacteria may, for instance, be effected by protoplast transformation or by using competent cells m a manner known per se .
  • the yeast organism may favorably be selected from a species of Saccharomyces or Schizosaccharomyces, e . g . , Saccharomyces cerevisiae.
  • the host cell may also be a filamentous fungus, e . g. , a strain belonging to a species of Aspergillus , most preferably Aspergillus oryzae or Aspergillus niger, or a strain of Fusarium, such as a strain of Fusarium oxysporium, Fusarium graminearum (the perfect state named Gribberella zeae, previously Sphaeria zeae, synonym wi th Gibberella roseum and Gibberella roseum f. sp .
  • a filamentous fungus e . g.
  • a strain belonging to a species of Aspergillus most preferably Aspergillus oryzae or Aspergillus niger
  • a strain of Fusarium such as a strain of Fusarium oxysporium, Fusarium graminearum (the perfect state named Gribberella zeae, previously Sphaeria zeae, synonym wi
  • Fusarium sulphureum in the prefect state named Gibberella puricaris, synonym with Fusarium trichothecioides , Fusarium bactridioides , Fusarium sambucium, Fusarium roseum, and Fusarium roseum var . graminearum) , Fusarium cerealis (synonym with Fusarium crokkwellnse) , or Fusarium venenatum .
  • the host cell is a protease deficient or protease minus strain.
  • This may for instance be the protease deficient strain of the genus Aspergillus, m particular a strain of A . oryzae, such as A . oryzae JaL125 having the alkaline protease gene named "alp" deleted.
  • This strain is described m WO 97/35956 (Novo Nordisk) .
  • Filamentous fungi cells may be transformed by a process involving protoplast formation and transformation of the protoplasts followed by regeneration of the cell wall m a manner known per se .
  • Aspergillus as a host microorganism is described EP 238 023 (Novo Nordisk) , the contents of which are hereby incorporated by reference.
  • the present invention relates to a method of producing an alpha-amylase variant of the invention, which method comprises cultivating a host cell under conditions conducive to the production of the variant and recovering the variant from the cells and/or culture medium.
  • the medium used to cultivate the cells may be any conventional medium suitable for growing the host cell m question and obtaining expression of the alpha-amylase variant of the invention. Suitable media are available from commercial suppliers or may be prepared according to published recipes ⁇ e . g. , as described m catalogues of the American Type Culture Collection) .
  • the alpha-amylase variant secreted from the host cells may conveniently be recovered from the culture medium by well-known procedures, including separating the cells from the medium by centrifugation or filtration, and precipitating protemaceous components of the medium by means of a salt such as ammonium sulphate, followed by the use of chromatographic procedures such as ion exchange chromatography, affinity chromatography, or the like.
  • the present invention provides a method of using alpha- amylase variants of the invention for producing glucose or maltose or the like from starch.
  • the method includes the steps of partially hydrolyzmg precursor starch m the presence of alpha-amylase and then further hydrolyzmg the release of D-glucose from the non-reducing ends of the starch or related oligo- and polysaccha ⁇ de molecules m the presence of glucoamylase by cleaving alpha- (1 ⁇ 4) and alpha- (1 ⁇ 6) glucosidic bonds.
  • the partial hydrolysis of the precursor starch utilizing alpha-amylase provides an initial breakdown of the starch molecules by hydrolyzmg internal alpha- (1 ⁇ 4) -linkages .
  • the initial hydrolysis using alpha- amylase is run at a temperature of approximately 105°C.
  • a very high starch concentration is processed, usually 30% to 40% solids.
  • the initial hydrolysis is usually carried out for five minutes at this elevated temperature.
  • the partially hydrolyzed starch can then be transferred to a second tank and incubated for approximately one hour at a temperature of 85° to 90°C to derive a dextrose equivalent (D.E.) of 10 to 15.
  • D.E. dextrose equivalent
  • the step of further hydrolyzing the release of D-glucose from the non-reducing ends of the starch or related oligo- and polysaccharides molecules in the presence of glucoamylase is normally carried out in a separate tank at a reduced temperature between 30° and 60 °C.
  • the temperature of the substrate liquid is dropped to between 55° and 60°C.
  • the pH of the solution is dropped from 6 to 6.5 to a range between 3 and 5.5.
  • the pH of the solution is 4 to 4.5.
  • the glucoamylase is added to the solution and the reaction is carried out for 24-72 hours, preferably 36-48 hours.
  • alpha- amylases may be used for starch liquefaction.
  • the invention relates to the use of an alpha- amylase variant of the invention in a starch conversion process.
  • the alpha-amylase variant of the invention may also be used in brewing processes.
  • High Maltose syrup production (55% maltose) A variant of the invention may be used for maltose production.
  • High maltose syrup is typically produced as follows :
  • Bacillus pullulanase such as PromozymeTM 600 L, 0.3 1/t DS (Novo Nordisk)) and alpha-amylase activity (e . g. , BAN 240 L or TermamylTM 120 L, type LS, 0.4 kg/t DS (Novo Nordisk)) for 24-41 hours.
  • the specific process time depends on the desired saccharide spectrum to be achieved.
  • "High Maltose Syrup” may be produced by first liquefying starch to DE 10-20 and then adjusting the pH and temperature to 55°C and a pH around 5.5, respectively, and subjecting the liquefied starch to a fungal alpha-amylase activity (e . g. . Bacillus stearothermophilus amylase, such as FungamylTM 800L (Novo Nordisk)) for 22-44 hours.
  • the dosage of fungal alpha-amylase depends on the saccharification time foreseen, e . g . , 200 g/t DS for 44 hours and 400 g/t DS for 22 hours .
  • the liquefied starch may adjusted to a temperature of 65°C and a pH around 5.0 and subjected to maltogenic alpha-amylase activity (e . g. , Bacillus stearothermophilus amylase, such as MaltogenaseTM 4000 L, 0.5- 1.0 1/t DS) , and pullulanase activity ( e . g. , Bacillus pullulanase, such as PromozymeTM 600 L, 0.5-1.0 1/t DS) for 18-42 hours .
  • maltogenic alpha-amylase activity e . g. , Bacillus stearothermophilus amylase, such as MaltogenaseTM 4000 L, 0.5- 1.0 1/t DS
  • pullulanase activity e . g.
  • Bacillus pullulanase such as PromozymeTM 600 L, 0.5-1.0 1/t DS
  • the alpha-amylase variant of the invention may also be used in baking processes.
  • the invention relates to the used of a variant of the invention for starch conversion, alcohol production, brewing, baking.
  • the invention also relates to a process of producing maltose syrup comprising the steps of:
  • the alpha-amylase used for liquefaction in step 1) may be any alpha-amylase.
  • Preferred alpha-amylase are Bacillus alpha- amylases, such as a Termamyl-like alpha-amylase, which including the B . licheniformis alpha-amylase (commercially available as TermamylTM (Novo Nordisk)), the B . amyloli quefaciens alpha-amylase (sold as BAN (Novo Nordisk) , the B . stearothermophilus alpha-amylase (sold as Termamyl"* 120 L type S) , The alpha-amylases derived from a strain of the Bacillus sp .
  • Alpha-amylases within the definition of "Termamyl-like alpha-amylase" are defined in for instance WO 96/23874 (Novo Nordisk) .
  • the invention relates to a process of producing maltose comprising the steps of:
  • an effective amount of glucoamylase is added in step 2) .
  • the syrup will in this embodiment (including treatment with a glucoamylase) not be maltose syrup, but syrup with a different sugar profile,
  • the glucoamylase may be an Aspergillus glucoamylase, in particular an Aspergillus niger glucoamylase.
  • the process comprising the steps of:
  • the invention relates to an immobilized alpha- amylase variant of the invention.
  • the alpha-amylase variant may be immobilized using any suitable method know in the art such as method used for glucose isomerase in US patent no. 4,687,742.
  • FUNGAMYL ® fungal alpha-amylase derived from Aspergillus oryzae (available from Novo Nordisk) and shown in SEQ ID NO : 2.
  • a . oryzae JaL125 Aspergillus oryzae IFO 4177 available from Institute for Fermention, Osaka; 17-25 Juso Hammachi 2- Chome Yodogawa-ku, Osaka, Japan, having the alkaline protease gene named "alp” (described by Murakami K et al . , (1991), Agric. Biol. Chem. 55, p. 2807-2811) deleted by a one step gene replacement method (described by G. May in "Applied Molecular Genetics of Filamentous Fungi” (1992), p. 1-25. Eds. J. R. Kinghorn and G. Turner; Blackie Academic and Professional) , using the A . oryzae pyrG gene as marker.
  • Strain JaL 125 is further disclosed in WO 97/35956 (Novo Nordisk) .
  • Saccharomyces cerevisiae YNG318 MAT ⁇ leu2- ⁇ 2 ura3-52 his4-539 pep4- ⁇ l [cir+]
  • YPD Yeast et al .
  • the mycelium is harvested by filtration through miracloth and washed with 200 ml of 0.6 M MgS04.
  • the mycelium is suspended in 15 ml of 1.2 M MgS0 4 , 10 mM aH2P0 4 , pH 5.8.
  • the suspension is cooled on ice and 1 ml of buffer containing 120 mg of NovozymTM 234 is added.
  • the suspension is filtered through miracloth, the filtrate transferred to a sterile tube and overlayed with 5 ml of 0.6 M sorbitol, 100 mM Tris-HCl, pH 7.0. Centrifugation is performed for 15 min. at 1000 g and the protoplasts are collected from the top of the MgS0 4 cushion. 2 volumes of STC (1.2 M sorbitol, 10 mM Tris-HCl, pH 7.5 , 10 mM CaCl 2 ) are added to the protoplast suspension and the mixture is centrifugated for 5 min. at 1000 g. The protoplast pellet is resuspended in 3 ml of STC and repelleted. This is repeated. Finally, the protoplasts are resuspended in 0.2-1 ml of STC.
  • p3SR2 an A . nidulans amdS gene carrying plasmid described in Hynes et al . , Mol . and Cel . Biol., Vol. 3, No. 8, 1430-1439, Aug. 1983
  • STC 10 micro liter of STC.
  • the mixture is left at room temperature for 25 minutes 0.2 ml of 60% PEG 4000 (BDH 29576), 10 mM CaCl 2 and 10 mM Tris-HCl, pH
  • the culture broth is filtrated and added ammonium sulphate (AMS) to a concentration of 1.7 M AMS and pH is adjusted to pH 5.
  • AMS ammonium sulphate
  • Precipitated material is removed by centrifugation on the solution containing alpha-amylase activity is applied on a Toyo Pearl Butyl column previously equilibrated in 1.7 M AMS, 20 mM sodium acetate, pH 5. Unbound material is washed out with the equilibration buffer.
  • Bound proteins are eluted with 10 mM sodium acetate, pH 4.5 using a linear gradient from 1.7 - 0 M AMS over 10 column volumes.
  • Glucoamylase containing fractions are collected ad dialysed against 20 mM sodium acetate, pH 4.5.
  • thermostable filter assay The libraries are screened in the thermostable filter assay described below.
  • Yeast libraries are plated on a sandwich of cellulose acetate (OE 67, Schleicher & Schuell, Dassel, Germany) - and nitrocellulose filters (Protran-Ba 85, Schleicher & Schuell, Dassel, Germany) on SC ura ' agar plates with 100 micro gram/ml ampicillin at 30°C for at least 72 hrs .
  • the colonies are replica plated to PVDF filters (Immobilon-P, Millipore, Bedford) activated with methanol for 1 min and subsequently washed in 0.1 M NaAc and then incubated at room temperature for 2 hours. Colonies are washed from PVDF filters with tap water.
  • Each filter sandwiches and PVDF filters are specifically marked with a needle before incubation in order to be able to localise positive variants on the filters after the screening.
  • the PVDF filters with bound variants are transferred to a container with 0.1 M NaAc, pH 4.5 and incubated at 47°C for 15 minutes.
  • the sandwich of cellulose acetate and nitrocellulose filters on SC ura-agar plates are stored at room temperature until use. After incubation, the residual activities are detected on plates containing 5% maltose, 1% agarose, 50 mM NaAc, pH 4.5.
  • the assay plates with PVDF filters are marked the same way as the filter sandwiches and incubated for 2 hrs. at 50°C.
  • the assay plates are stained with Glucose GOD perid (Boehringer Mannheim GmbH, Germany) . Variants with residual activity are detected on assay plates as dark green spots on white background. The improved variants are located on the storage plates. Improved variants are re-screened twice under the same conditions as the first screen.
  • FAU Fungal Alpha-Amylase Unit
  • Acid alpha-amylase activity is measured in AFAU (Acid Fungal Alpha-amylase Units) , which are determined relative to an enzyme standard.
  • the standard used is AMG 300 L (from Novo Nordiks) .
  • the neutral alpha-amylase in this AMG falls after storage at room temperature for 3 weeks from approx. 1 FAU/mL to below 0.05 FAU/mL .
  • the acid alpha-amylase activity in this AMG standard is determined in accordance with AF 9 1/3 (Novo method for the determination of fungal alpha-amylase) .
  • 1 FAU is defined as the amount of enzyme, which degrades 5.260 mg starch dry matter per hour under standard conditions.
  • Iodine forms a blue complex with starch but not with its degradation products.
  • the intensity of colour is therefore directly proportional to the concentration of starch.
  • Amylase activity is determined using reverse colorimetry as a reduction in the concentration of starch under specified analytic conditions.
  • Substrate starch, approx. 0.17 g/L
  • Enzyme working range 0.01-0.04 AFAU/mL Further details can be found in EB-SM-0259.02/01 available on request from Novo Nordisk, and incorporated by reference.
  • Thermal/pH Stability Determination of Variant of the invention The thermal stability of variants of the invention is tested using the following method: 950 micro liter 0.1 M
  • Citrate + 4.3 mM Ca + buffer is incubated for 1 hour at 60°C. 50 micro liter enzyme in buffer (4 AFAU/ml) is added. 2 x 40 micro liter samples are taken at 0 and 60 minutes and chilled on ice. The activity (AFAU/ml) measured before incubation (0 minutes) is used as reference (100%) . The decline in percent is calculated as a function of the incubation time.
  • the test is repeated using different temperatures, for instance 50, 60, 70, 80 and
  • the random mutagenesis may be carried out as follows: 1. Select regions of interest for modification in the parent enzyme, 2. Decide on mutation sites and non-mutated sites in the selected region,
  • Suitable dope algorithms for use in step 6 are well known in the art.
  • One such algorithm is described by Tomandl , D. et al . ,
  • TAKA-amylase enzyme FungamylTM shown in SEQ ID NOS: 1 and 2
  • the commercial kit Chameleon double-stranded, site-directed mutagenesis kit is used according to the manufacturer's instructions.
  • the gene encoding the amylase enzyme in question is in plasmid pTAKA17 (EP 238,023, figure 2 and Example 2).
  • the Seal site of the Ampicillin gene of pTAKA17 is changed to a Mlul site by use of the following primer:
  • Primer 7258 5'p gaa tga ctt ggt tga cgc gtc ace agt cac 3' (SEQ ID NO: 3)
  • the Seal site in an intron in the Amylase gene is removed using the primer
  • the desired mutation is introduced into the amylase gene in question by addition of an appropriate oligos comprising the desired mutation.
  • an oligo is design:
  • the pTAKA17 vector comprising the amylase gene in question is then used as a template for DNA polymerase, DNA ligase (for ligation to 5'Phosphate (5'P) on the oligoes), and the oligoes 7258, primer 1 and primer 2.
  • DNA polymerase for ligation to 5'Phosphate (5'P) on the oligoes
  • 5'P 5'Phosphate
  • DNA-prep. are made, and the introduction of the mutation is verified by sequencing.
  • the DNA prep is transformed in Aspergillus oryzae host cell as describe in the "Materials & Methods" section and the transformants are screened for amylase activity.
  • Example 2 The DNA prep, is transformed in Aspergillus oryzae host cell as describe in the "Materials & Methods" section and the transformants are screened for amylase activity.
  • Example 1 The variant constructed in Example 1 is tested for increased thermostability in accordance with the thermo stability determination assay disclosed in the "Materials & Methods" section.
  • Example 1 The variant constructed in Example 1 is tested for increased stability at acidic pH in accordance with the pH stability determination assay disclosed in the "Materials & Methods" section.

Abstract

L'invention concerne un variant d'une alpha-amylase fongique du type Fungamyle apparenté qui présente une stabilité thermique améliorée à pH acide qui convient, par exemple, pour des procédés utilisant l'amidon.
EP00974351A 1999-11-10 2000-11-10 Variants alpha-amylase du type fungamyle Ceased EP1230351A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP08152275A EP1980614A3 (fr) 1999-11-10 2000-11-10 Variantes d'alpha-amylase comme le fungamyl

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK161799 1999-11-10
DKPA199901617 1999-11-10
PCT/DK2000/000626 WO2001034784A1 (fr) 1999-11-10 2000-11-10 Variants alpha-amylase du type fungamyle

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP08152275A Division EP1980614A3 (fr) 1999-11-10 2000-11-10 Variantes d'alpha-amylase comme le fungamyl

Publications (1)

Publication Number Publication Date
EP1230351A1 true EP1230351A1 (fr) 2002-08-14

Family

ID=8106583

Family Applications (2)

Application Number Title Priority Date Filing Date
EP08152275A Withdrawn EP1980614A3 (fr) 1999-11-10 2000-11-10 Variantes d'alpha-amylase comme le fungamyl
EP00974351A Ceased EP1230351A1 (fr) 1999-11-10 2000-11-10 Variants alpha-amylase du type fungamyle

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP08152275A Withdrawn EP1980614A3 (fr) 1999-11-10 2000-11-10 Variantes d'alpha-amylase comme le fungamyl

Country Status (6)

Country Link
EP (2) EP1980614A3 (fr)
JP (1) JP2003513666A (fr)
CN (2) CN1390252A (fr)
AR (1) AR026433A1 (fr)
AU (1) AU1269601A (fr)
WO (1) WO2001034784A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101880679B (zh) * 2010-01-21 2012-07-04 广西大学 嗜热链霉菌麦芽糖α-淀粉酶基因及其应用

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2457850A1 (fr) * 2001-08-16 2003-02-27 Dsm Ip Assets B.V. Nouvelles amylases et leurs utilisations
WO2004055178A1 (fr) 2002-12-17 2004-07-01 Novozymes A/S Alpha-amylases thermostables
US20040219649A1 (en) * 2003-03-10 2004-11-04 Novozymes A/S Alcohol product processes
EP1633878A1 (fr) * 2003-05-30 2006-03-15 Novozymes A/S Procedes de fabrication de produits d'alcool
CA2534710A1 (fr) 2003-08-22 2005-03-03 Novozymes A/S Variants d'alpha-amylases fongiques
DE102004047777B4 (de) 2004-10-01 2018-05-09 Basf Se Alpha-Amylase-Varianten mit erhöhter Lösungsmittelstabilität, Verfahren zu deren Herstellung sowie deren Verwendung
CN104204216A (zh) * 2012-03-28 2014-12-10 丹尼斯科美国公司 高麦芽糖糖浆制备方法
WO2014194032A1 (fr) 2013-05-29 2014-12-04 Danisco Us Inc. Métalloprotéases inédites
EP3004342B1 (fr) 2013-05-29 2023-01-11 Danisco US Inc. Métalloprotéases inédites
EP3110833B1 (fr) 2013-05-29 2020-01-08 Danisco US Inc. Métalloprotéases inédites
WO2014194054A1 (fr) 2013-05-29 2014-12-04 Danisco Us Inc. Métalloprotéases inédites
EP3553173B1 (fr) 2013-12-13 2021-05-19 Danisco US Inc. Protéases de sérine du bacille gibsonii-clade
EP3080262B1 (fr) 2013-12-13 2019-02-06 Danisco US Inc. Sérine protéases provenant de bacillus
WO2015095046A1 (fr) 2013-12-16 2015-06-25 E. I. Du Pont De Nemours And Company Utilisation de poly(éthers d'alpha-1,3-glucane) en tant que modificateurs de viscosité
ES2835703T3 (es) 2013-12-18 2021-06-23 Nutrition & Biosciences Usa 4 Inc Eteres de poli alfa-1,3-glucano catiónicos
WO2015123323A1 (fr) 2014-02-14 2015-08-20 E. I. Du Pont De Nemours And Company Poly-alpha-1,3-1,6-glucanes utilisables en vue de la modification de la viscosité
ES2734726T3 (es) 2014-03-11 2019-12-11 Du Pont Poli alfa-1,2-glucano oxidado como reforzante de detergente
CN103881993B (zh) * 2014-03-13 2015-11-18 南宁邦尔克生物技术有限责任公司 一种耐酸性高温β-淀粉酶的突变体TBA-H2及其应用
JP6585698B2 (ja) 2014-03-21 2019-10-02 ダニスコ・ユーエス・インク バチルス（Ｂａｃｉｌｌｕｓ）種のセリンプロテアーゼ
US9771548B2 (en) 2014-06-19 2017-09-26 E I Du Pont De Nemours And Company Compositions containing one or more poly alpha-1,3-glucan ether compounds
US9714403B2 (en) 2014-06-19 2017-07-25 E I Du Pont De Nemours And Company Compositions containing one or more poly alpha-1,3-glucan ether compounds
WO2016061438A1 (fr) 2014-10-17 2016-04-21 Danisco Us Inc. Sérines protéases de l'espèce bacillus
DK3212662T3 (da) 2014-10-27 2020-07-20 Danisco Us Inc Serinproteaser
WO2016069544A1 (fr) 2014-10-27 2016-05-06 Danisco Us Inc. Sérines protéases
EP3212782B1 (fr) 2014-10-27 2019-04-17 Danisco US Inc. Sérine protéases
EP3212781B1 (fr) 2014-10-27 2019-09-18 Danisco US Inc. Sérine-protéases
EP3224357A1 (fr) 2014-10-27 2017-10-04 Danisco US Inc. Sérine-protéases de l'espèce bacillus
CA2969242A1 (fr) 2014-12-23 2016-06-30 E.I. Du Pont De Nemours And Company Cellulose produite par voie enzymatique
JP7274819B2 (ja) 2015-05-13 2023-05-17 ダニスコ・ユーエス・インク ＡｐｒＬ－ＣＬＡＤＥプロテアーゼ変異体及びその使用
ES2962329T3 (es) 2015-06-09 2024-03-18 Danisco Us Inc Encapsulados de estallido osmótico
WO2016201069A1 (fr) 2015-06-09 2016-12-15 Danisco Us Inc Particules contenant une enzyme basse densité
WO2016201040A1 (fr) 2015-06-09 2016-12-15 Danisco Us Inc. Suspension d'enzyme activée par l'eau
WO2016205755A1 (fr) 2015-06-17 2016-12-22 Danisco Us Inc. Protéases à sérines du clade du bacillus gibsonii
EP3334862A2 (fr) 2015-08-14 2018-06-20 Basf Se Composition de traitement de surface aqueuse pour papier et carton
BR112018008946A2 (pt) 2015-11-05 2020-11-03 Danisco Us Inc. mananases de paenibacillus sp.
US20180320158A1 (en) 2015-11-05 2018-11-08 Danisco Us Inc. Paenibacillus and bacillus spp. mannanases
EP3374400B1 (fr) 2015-11-13 2022-04-13 Nutrition & Biosciences USA 4, Inc. Compositions de fibres de glucane utiles pour la lessive et l'entretien des tissus
US10822574B2 (en) 2015-11-13 2020-11-03 Dupont Industrial Biosciences Usa, Llc Glucan fiber compositions for use in laundry care and fabric care
EP3374488B1 (fr) 2015-11-13 2020-10-14 DuPont Industrial Biosciences USA, LLC Compositions de fibre de glucane à utiliser dans l'entretien du linge et l'entretien de tissu
BR112018011755A2 (pt) 2015-12-09 2018-12-04 Danisco Us Inc variantes combinatórias de alfa-amilase
WO2017106676A1 (fr) 2015-12-18 2017-06-22 Danisco Us Inc Polypeptides ayant une activité endoglucanase et leurs utilisations
CA3022875A1 (fr) 2016-05-03 2017-11-09 Danisco Us Inc Variants de protease et leurs utilisations
EP3845642B1 (fr) 2016-05-05 2023-08-09 Danisco US Inc. Variantes de protéase et leurs utilisations
CA3026064A1 (fr) 2016-05-31 2017-12-07 Danisco Us Inc. Variants de protease et leurs utilisations
CN109563497A (zh) 2016-06-17 2019-04-02 丹尼斯科美国公司 蛋白酶变体及其用途
CN106047844B (zh) * 2016-08-01 2020-05-22 安徽工程大学 一种具有高麦芽糖生成率的真菌α-淀粉酶变体及其制备方法
WO2018085524A2 (fr) 2016-11-07 2018-05-11 Danisco Us Inc Composition détergente pour le linge
CN110312795A (zh) 2016-12-21 2019-10-08 丹尼斯科美国公司 蛋白酶变体及其用途
EP3559226B1 (fr) 2016-12-21 2023-01-04 Danisco US Inc. Sérine-protéases du clade du bacillus gibsonii
WO2018169750A1 (fr) 2017-03-15 2018-09-20 Danisco Us Inc Sérine protéases de type trypsine et leurs utilisations
US20200040283A1 (en) 2017-03-31 2020-02-06 Danisco Us Inc Delayed release enzyme formulations for bleach-containing detergents
CA3067837A1 (fr) 2017-06-30 2019-01-03 Danisco Us Inc Particules contenant une enzyme a faible agglomeration
CN111373039A (zh) 2017-11-29 2020-07-03 丹尼斯科美国公司 具有改善的稳定性的枯草杆菌蛋白酶变体
CA3086202A1 (fr) 2017-12-21 2019-06-27 Danisco Us Inc. Granules thermofusibles contenant des enzymes, comprenant un deshydratant thermotolerant
WO2019156670A1 (fr) 2018-02-08 2019-08-15 Danisco Us Inc. Particules de matrice de cire résistant à la chaleur pour encapsulation d'enzymes
MX2020013319A (es) 2018-06-12 2021-02-22 Novozymes As Menos azúcar añadido en productos horneados.
US20210363470A1 (en) 2018-06-19 2021-11-25 Danisco Us Inc Subtilisin variants
US20210214703A1 (en) 2018-06-19 2021-07-15 Danisco Us Inc Subtilisin variants
US20210189295A1 (en) 2018-08-30 2021-06-24 Danisco Us Inc Enzyme-containing granules
US20220033737A1 (en) 2018-09-27 2022-02-03 Danisco Us Inc Compositions for medical instrument cleaning
US20230028935A1 (en) 2018-11-28 2023-01-26 Danisco Us Inc Subtilisin variants having improved stability
US20220220419A1 (en) 2019-05-24 2022-07-14 Danisco Us Inc Subtilisin variants and methods of use
CN114174486A (zh) 2019-06-06 2022-03-11 丹尼斯科美国公司 用于清洁的方法和组合物
EP4204553A1 (fr) 2020-08-27 2023-07-05 Danisco US Inc. Enzymes et compositions d'enzymes pour le nettoyage
WO2022090562A1 (fr) 2020-11-02 2022-05-05 Novozymes A/S Produits cuits et précuits à variants d'amg thermostables à partir de penicillium
EP4284906A1 (fr) 2021-01-29 2023-12-06 Danisco US Inc. Compositions pour le nettoyage et procédés associés
CN117616120A (zh) 2021-06-30 2024-02-27 丹尼斯科美国公司 变体脂肪酶及其用途
WO2023034486A2 (fr) 2021-09-03 2023-03-09 Danisco Us Inc. Compositions de blanchisserie pour le nettoyage
WO2023039270A2 (fr) 2021-09-13 2023-03-16 Danisco Us Inc. Granulés contenant un agent bioactif
WO2023114932A2 (fr) 2021-12-16 2023-06-22 Danisco Us Inc. Variants de subtilisine et procédés d'utilisation
WO2023114936A2 (fr) 2021-12-16 2023-06-22 Danisco Us Inc. Variants de subtilisine et procédés d'utilisation
WO2023114939A2 (fr) 2021-12-16 2023-06-22 Danisco Us Inc. Variants de subtilisine et procédés d'utilisation
WO2023168234A1 (fr) 2022-03-01 2023-09-07 Danisco Us Inc. Enzymes et compositions enzymatiques pour le nettoyage
CN114908072B (zh) * 2022-03-10 2023-08-15 江苏省奥谷生物科技有限公司 一种β-淀粉酶突变体及其在麦芽糖制备中的应用
WO2023213424A1 (fr) 2022-05-04 2023-11-09 Novozymes A/S Brassage avec variants d'amg thermostables
WO2023250301A1 (fr) 2022-06-21 2023-12-28 Danisco Us Inc. Procédés et compositions de nettoyage comprenant un polypeptide ayant une activité de thermolysine
WO2024046594A1 (fr) 2022-09-01 2024-03-07 Novozymes A/S Cuisson avec des variants thermostables de glucosidase amg (ec 3.2.1.3) et peu ou pas d'émulsifiant ajouté
WO2024046595A1 (fr) 2022-09-01 2024-03-07 Novozymes A/S Cuisson à l'aide de variants d'amyloglucosidase (amg) thermostables (ec 3.2.1.3) et à faible teneur en sucre ajouté
WO2024050346A1 (fr) 2022-09-02 2024-03-07 Danisco Us Inc. Compositions détergentes et procédés associés
WO2024050339A1 (fr) 2022-09-02 2024-03-07 Danisco Us Inc. Variants de mannanases et procédés d'utilisation
WO2024050343A1 (fr) 2022-09-02 2024-03-07 Danisco Us Inc. Variants de subtilisine et procédés associés

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4760025A (en) 1984-05-29 1988-07-26 Genencor, Inc. Modified enzymes and methods for making same
DK111185A (da) 1985-03-12 1986-09-13 Novo Industri As Xyloseisomerase, fremgangsmaade til fremstilling deraf, immobiliseret xyloseisomerase og fremgangsmaade til isomerisering af glucose til fructose
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
DK122686D0 (da) 1986-03-17 1986-03-17 Novo Industri As Fremstilling af proteiner
DE3886221T3 (de) 1987-09-04 2000-12-21 Novo Nordisk As VERFAHREN ZUR HERSTELLUNG VON PROTEINPRODUKTEN IN -i(ASPERGILLUS) UND PROMOTOREN ZUR VERWENDUNG IN -i(ASPERGILLUS).
DE3909096A1 (de) 1989-03-20 1990-09-27 Garabed Antranikian Alpha-amylase
AU639570B2 (en) 1990-05-09 1993-07-29 Novozymes A/S A cellulase preparation comprising an endoglucanase enzyme
DK154292D0 (da) * 1992-12-23 1992-12-23 Novo Nordisk As Nyt enzym
BR9407767A (pt) 1993-10-08 1997-03-18 Novo Nordisk As Variante de enzima &-amilase uso da mesma construção de DNA vetor de express o recombinante célula processos para produzir uma &-amilase hibrida e para preparar uma variante de uma &-amilase aditivo detergente e composições detergentes
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
EP0753057B1 (fr) 1994-03-29 2005-09-21 Novozymes A/S Amylase alcaline issue d'un bacille
WO1995029224A1 (fr) * 1994-04-22 1995-11-02 The Procter & Gamble Company Compositions de detergent contenant une amylase
DE4422198C2 (de) 1994-06-24 1997-08-28 Audi Ag Verfahren zum Steuern der elektrischen Beheizung eines Katalysators
BR9607013B1 (pt) * 1995-02-03 2011-03-09 processo de construção de uma variante de uma alfa-amilase de bacillus original derivada de uma cepa de b. licheniformis, de b. amyloliquefaciens, de b. stearothermophilus ou de um bacillus sp. alcalofìlico.
AR000862A1 (es) 1995-02-03 1997-08-06 Novozymes As Variantes de una ó-amilasa madre, un metodo para producir la misma, una estructura de adn y un vector de expresion, una celula transformada por dichaestructura de adn y vector, un aditivo para detergente, composicion detergente, una composicion para lavado de ropa y una composicion para la eliminacion del
ES2257774T3 (es) 1996-03-27 2006-08-01 Novozymes A/S Hongos filamentosos carentes de proteasa alcalina.
JP4290763B2 (ja) * 1996-04-30 2009-07-08 ノボザイムス アクティーゼルスカブ α―アミラーゼ変異体
AU9737398A (en) * 1997-10-30 1999-05-24 Novo Nordisk A/S Alpha-amylase mutants

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0134784A1 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101880679B (zh) * 2010-01-21 2012-07-04 广西大学 嗜热链霉菌麦芽糖α-淀粉酶基因及其应用

Also Published As

Publication number Publication date
JP2003513666A (ja) 2003-04-15
EP1980614A3 (fr) 2009-04-08
CN1390252A (zh) 2003-01-08
AU1269601A (en) 2001-06-06
WO2001034784A1 (fr) 2001-05-17
CN1654641A (zh) 2005-08-17
EP1980614A2 (fr) 2008-10-15
AR026433A1 (es) 2003-02-12

Similar Documents

Publication Publication Date Title
WO2001034784A1 (fr) Variants alpha-amylase du type fungamyle
US8722369B2 (en) Glucoamylase variants
US8426183B2 (en) Glucoamylase variants
EP1097196B1 (fr) Variants de glucoamylase
US7919281B2 (en) Glucoamylase variants
US20110159545A1 (en) Fungamyl-like Alpha-Amylase Variants
US6329186B1 (en) Glucoamylases with N-terminal extensions
EP1137763A1 (fr) Gluco-amylases a extensions n-terminales
EP1914306A2 (fr) Variantes de la glucoamylase

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020610

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17Q First examination report despatched

Effective date: 20040203

APBN Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2E

APBD Information on interlocutory revision deleted

Free format text: ORIGINAL CODE: EPIDOSDIRAPE

APBV Interlocutory revision of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNIRAPE

APBR Date of receipt of statement of grounds of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA3E

APAF Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNE

APBT Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9E

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20080306